
Karl Peter Bohn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1351485/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical performance of long axial field of view PET/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2395-2404.	6.4	126
2	Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2978-2989.	6.4	58
3	Digital PET/CT allows for shorter acquisition protocols or reduced radiopharmaceutical dose in [18F]-FDG PET/CT. Annals of Nuclear Medicine, 2021, 35, 485-492.	2.2	34
4	A comprehensive review of imaging findings in COVID-19 -Âstatus in early 2021. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2500-2524.	6.4	31
5	Combination of Forced Diuresis with Additional Late Imaging in ⁶⁸ Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake. Journal of Nuclear Medicine, 2021, 62, 1252-1257.	5.0	26
6	Feasibility of late acquisition [68Ga]Ga-PSMA-11 PET/CT using a long axial field-of-view PET/CT scanner for the diagnosis of recurrent prostate cancer—first clinical experiences. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4456-4462.	6.4	25
7	A cross-scanner and cross-tracer deep learning method for the recovery of standard-dose imaging quality from low-dose PET. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1843-1856.	6.4	24
8	The influence of digital PET/CT on diagnostic certainty and interrater reliability in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer. European Radiology, 2021, 31, 8030-8039.	4.5	19
9	Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2436-2444.	6.4	19
10	Quantitative analysis of regional distribution of tau pathology with 11C-PBB3-PET in a clinical setting. PLoS ONE, 2022, 17, e0266906.	2.5	7
11	PSMA-Ligand Uptake in Disseminated Epidermoid Cysts in a PSMA PET/CT of a Patient With Recurrent Prostate Cancer. Clinical Nuclear Medicine, 2021, 46, e598-e599.	1.3	3
12	Comparison of MRI-based and PET-based image pre-processing for quantification of 11C-PBB3 uptake in human brain. Zeitschrift Fur Medizinische Physik, 2021, 31, 37-47.	1.5	1
13	Authors' reply: PSMA-PET: is the time to say goodbye to metabolic radiopharmaceuticals in prostate cancer?. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2307-2308.	6.4	0